Practice-Changing Melanoma Research From ECOG-ACRIN Receives the 2023 Paper of the Year Distinction from the Journal of Clinical Oncology
And the 2023 Paper of the Year distinction by the Journal of Clinical Oncology goes to … a team of melanoma researchers with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). The recognition is for the results of the DREAMseq randomized phase 3 clinical trial. DREAMseq (EA6134) showed an optimal treatment sequence for combination therapy in patients with advanced melanoma with […]